Bolt Biotherapeutics

Bolt Biotherapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bolt Biotherapeutics (BOLT) as of Oct 17, 2026 is -34.63 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -73.05 M USD — a change of -52.59% (higher).

EBITDA

-34.63 MUSD

YoY

-52.59%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bolt Biotherapeutics is 2025 -34.63 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bolt Biotherapeutics was 2024 -73.05 M USD. It decreases by -52.59% higher compared to the previous year.

The Bolt Biotherapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-11.63 M USD
Jan 1, 2019
-30.97 M USD
Jan 1, 2020
-49.18 M USD
Jan 1, 2021
-92.79 M USD
Jan 1, 2022
-90.32 M USD
Jan 1, 2023
-76.20 M USD
Jan 1, 2024
-73.05 M USD
Jan 1, 2025
-34.63 M USD
The Bolt Biotherapeutics EBITDA history
YEAREBITDAYoY
-34.63 MUSD-52.59%
-73.05 MUSD-4.13%
-76.20 MUSD-15.64%
-90.32 MUSD-2.66%
-92.79 MUSD+88.66%
-49.18 MUSD+58.81%
-30.97 MUSD+166.31%
-11.63 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bolt Biotherapeutics Stock analysis

What does Bolt Biotherapeutics do? Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California. It develops immunotherapies for cancer treatment using its proprietary Boltbody ISAC platform, which combines tumor-targeting antibodies with immune-stimulating payloads. The company employs 94 full-time staff and completed an IPO on February 5, 2021. Its lead program, BDC-1001, targets HER2 and has advanced to Phase II trials following a dose-escalation study. BDC-3042 is a Dectin-2 agonist antibody program targeting tumor-associated macrophages. Bolt Biotherapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bolt Biotherapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bolt Biotherapeutics is -34.63 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bolt Biotherapeutics changed from -73.05 M USD to -34.63 M USD, representing a -52.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Bolt Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Bolt Biotherapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Bolt Biotherapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Bolt Biotherapeutics